Alendrate 70 mg
Pregnancy: Contraindicated in pregnancy. Lactation: Contraindicated or not recommended. Contraindications: Renal impairment with GFR <35 mL/min. Oesophageal abnormalities stricture achalasia or inability to remain upright for 30 min after dosing. Hypocalcaemia.
Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women treatment of glucocorticoid-induced osteoporosis and Paget's disease of bone.
Tablet 10 mg: Treatment of osteoporosis in post-menopausal women to prevent fractures. Treatment of glucocorticoid induced osteoporosis and prevention of bone
loss in men and women. Prevention of osteoporosis in post-menopausal women.
OW (Once Weekly) Tablet 70 mg: Treatment of post-menopausal osteoporosis to reduce risk of vertebral and hip fractures.
Oesophageal ulcer abdominal pain dyspepsia dysphagia abdominal distension musculoskeletal pain headache. Rarely rash angioedema oesophageal stricture
oropharyngeal ulceration uveitis dizziness acid regurgitation alopecia gastric and duodenal ulcers pruritus joint swelling asthenia peripheral oedema.
Precautions: Upper GI disorders. Treat hypocalcaemia or vitamin D deficiency firrst. Warn patient to report any symptoms such as diffficulty in swallowing retrosternal
pain or worsening heartburn and to discontinue immediately. Hypoparathyroidism calcium malabsorption. Maintain adequate calcium and vit D intake. Risk of rare
osteonecrosis of thejaw; advise patients to maintain good oral hygiene. Risk of rare atypical femoral fracture; advise patients report thigh hip or groin pain.